Clinical trial
A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT02162836 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 27, 2014
- Completion date
- May 27, 2019
- Enrollment
- 6 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.